Scientific guidelines with SmPC recommendations
Scientific guidelines with SmPC recommendations EMA/813125/2012 Page 3/5 . Guidelines Reference to specific SmPC section(s) Evaluation of the pharmacokinetics of medicinal products in
Download Scientific guidelines with SmPC recommendations
Information
Domain:
Source:
Link to this page:
Documents from same domain
Q12 Step 2b Technical and regulatory …
www.ema.europa.euICH guideline Q12 on technical and regulatory considerations for pharmaceutical product lifecycle management EMA/CHMP/ICH/804273/2017 Page 3/36
Guideline on good pharmacovigilance practices …
www.ema.europa.eu9 December 2013 . EMA/816292/2011 Rev 1* Guideline on good pharmacovigilance practices (GVP) Module VII – Periodic safety update report (Rev 1)
Guideline on good pharmacovigilance practices (GVP)
www.ema.europa.euGuideline on good pharmacovigilance practices (GVP) – Module IX (Rev 1) EMA/827661/2011 Rev 1 Page 2/25
Guideline on good pharmacovigilance practices …
www.ema.europa.euGuideline on good pharmacovigilance practices (GVP) – Module VIII (Rev 3) EMA/813938/2011 Rev 3 Page 2/28
Guideline for good clinical practice E6(R2)
www.ema.europa.euGuideline for good clinical practice E6(R2) EMA/CHMP/ICH/135/1995 Page 2/70 Document History First Codification History Date New Codification
Guideline for good clinical practice E6(R2)
www.ema.europa.euGuideline for good clinical practice E6(R2) EMA/CHMP/ICH/135/1995 Page 2/75 10 Document History 11 First Codification History Date New Codification November
Guideline on good pharmacovigilance practices …
www.ema.europa.euharmful physical or psychological effects [DIR 2001/83/EC Art 1(1 6)]. 74 Adverse event (AE); synonym: Adverse experience 75 Any untoward medical occurrence in a patient or clinical- trial subject administered a medicinal product
European Medicines Agency
www.ema.europa.eu© EMEA 2006 2 SPECIFICATIONS: TEST PROCEDURES AND ACCEPTANCE CRITERIA FOR BIOTECHNOLOGICAL/BIOLOGICAL PRODUCTS ICH Harmonised Tripartite Guideline
products1/traditional herbal medicinal products
www.ema.europa.euThere is no expectation that existing herbal medicinal products on the market will be affected by this guideline, with the exception of traditional herbal medicinal products for human use that were already
Q7 Q&A - good manufacturing practice for active ...
www.ema.europa.euICH guideline Q7 on good manufacturing practice for active pharmaceutical ingredients – questions and answers EMA/CHMP/ICH/468930/2015 Page 2/37
Related documents
AUSTRALIAN PRODUCT INFORMATION PANADOL ... - …
www.medicines.org.au3 Paediatric use Not recommended for children under 12 years of age. Effects on laboratory tests No data available. 4.5 INTERACTIONS WITH OTHER MEDICINES AND OTHER FORMS OF INTERACTIONS The following interactions with paracetamol have been noted:
Public Assessment Report Decentralised Procedure …
www.mhra.gov.ukPENTHROX 3mL inhalation vapour, liquid UK/H/5542/001/DC 7 A modified Paediatric Investigation Plan (PIP) was agreed with the Paediatric Committee (PDCO) in November 2012.
Emollient formulary and guidelines - NHS Redbridge CCG
www.redbridgeccg.nhs.uk2 Content Page number Formulary products 3 Leave on emollients 4 Prescribing guide: Points to consider and types of emollients 5 Quantities of emollients to be prescribed 6
DEVELOPMENT OF PAEDIATRIC MEDICINES: POINTS TO …
www.who.intworking document qas/08.257/rev.3 page 2 schedule for the proposed adoption process of document qas/08.257: development of paediatric medicines: points to consider in
DEVELOPMENT OF PAEDIATRIC MEDICINES: …
www.who.intWorking document QAS/08.257 February 2008 RESTRICTED DEVELOPMENT OF PAEDIATRIC MEDICINES: PHARMACEUTICAL DEVELOPMENT. POINTS TO CONSIDER At the forty-second meeting of the WHO Expert Committee on Specifications for Pharmaceutical
REGULATORY STRATEGIES AND PRACTICAL ASPECTS FOR THE ...
dgra.deregulatory strategies and practical aspects for the development and authorisation of orphan medicinal products in the european union wissenschaftliche prüfungsarbeit